Clarius Group LLC Has $1.13 Million Stock Position in Danaher Co. (NYSE:DHR)

Clarius Group LLC lifted its holdings in shares of Danaher Co. (NYSE:DHR) by 8.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,913 shares of the conglomerate’s stock after purchasing an additional 376 shares during the period. Clarius Group LLC’s holdings in Danaher were worth $1,128,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Decker Retirement Planning Inc. acquired a new position in Danaher during the 4th quarter worth about $31,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Danaher in the third quarter worth approximately $39,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher in the third quarter valued at approximately $40,000. FSA Wealth Management LLC acquired a new stake in Danaher during the 3rd quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC bought a new position in Danaher during the 3rd quarter worth approximately $55,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $238.41 on Friday. The firm has a market capitalization of $172.20 billion, a P/E ratio of 45.50, a P/E/G ratio of 4.23 and a beta of 0.83. Danaher Co. has a 52 week low of $222.53 and a 52 week high of $281.70. The stock has a 50 day moving average price of $234.85 and a two-hundred day moving average price of $253.32. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period last year, the firm earned $2.02 earnings per share. The firm’s revenue was up 3.1% on a year-over-year basis. Equities analysts forecast that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. KeyCorp increased their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a report on Thursday, October 31st. Evercore ISI upped their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Scotiabank assumed coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price for the company. Finally, TD Cowen increased their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.